Intracoronary reopro during percutaneous coronary intervention in acute and stable patient can influence stent thrombosis formation (IRPASST) study

Intracoronary reopro during percutaneous coronary intervention in acute and stable patient can influence stent thrombosis formation (IRPASST) study

Background: In patients with acute myocardial infarction or unstable angina undergoing coronary angioplasty, abciximab reduces major adverse cardiac events (MACE). Most clinical trials have studied mainly intravenous administration. Intracoronary (IC) bolus application of abciximab causes very high...

Full description

Bibliographic Details
Main Authors: Mohammed Balghith, Ali Al-Ghamdi, El harif Zain, Ahmed Al-Saileek
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2013-01-01
Series:Heart Views
Subjects:
Abciximab
acute coronary artery disease
intracoronary
intravenous
stent thrombosis
tirofiban
Online Access:http://www.heartviews.org/article.asp?issn=1995-705X;year=2013;volume=14;issue=2;spage=62;epage=67;aulast=Balghith

Internet

http://www.heartviews.org/article.asp?issn=1995-705X;year=2013;volume=14;issue=2;spage=62;epage=67;aulast=Balghith

Similar Items